Trial Outcomes & Findings for Stimulation to Improve Memory (NCT NCT03875326)

NCT ID: NCT03875326

Last Updated: 2026-07-02

Results Overview

Primary outcome focuses on default mode network (DMN) between-network functional connectivity because the lateral temporal cortex is a core component of the DMN. Between-network functional connectivity is estimated from fMRI data as strength of temporal coupling between the DMN and other high-level (association) brain networks. For each participant and time point, correlation-based connectivity (Pearson r; Fisher r-to-z transformed; arbitrary units) computed between DMN regions and other regions of the association cortex defined using standard functional atlas. Higher values reflect stronger functional connectivity between DMN and other regions. A Z-score's range is infinite. Expected value is between -3 to 3. Analyses conducted separately for amyloid negative (A-) and amyloid positive (A+) participants. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

233 participants

Primary outcome timeframe

Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Results posted on

2026-07-02

Participant Flow

Number enrolled reflects the number of people who consented and were determined to be eligible for participation.

Participant milestones

Participant milestones
Measure
Sham Stimulation
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. Sham: Participants will receive sham (placebo) HD-tDCS for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. 1 mA HD-tDCS: Participants will receive HD-tDCS at 1 mA for 30 minutes, for between 5-30 sessions.
2 mA Dosage Stimulation
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. 2 mA HD-tDCS: Participants will receive HD-tDCS at 2 mA for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. 3 mA HD-tDCS: Participants will receive HD-tDCS at 3 mA for 30 minutes, for between 5-30 sessions.
Main Study
STARTED
59
59
58
57
Main Study
COMPLETED
58
56
55
56
Main Study
NOT COMPLETED
1
3
3
1
Voluntary Study Expansion
STARTED
32
24
31
28
Voluntary Study Expansion
COMPLETED
32
24
31
28
Voluntary Study Expansion
NOT COMPLETED
0
0
0
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Sham Stimulation
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. Sham: Participants will receive sham (placebo) HD-tDCS for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. 1 mA HD-tDCS: Participants will receive HD-tDCS at 1 mA for 30 minutes, for between 5-30 sessions.
2 mA Dosage Stimulation
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. 2 mA HD-tDCS: Participants will receive HD-tDCS at 2 mA for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. 3 mA HD-tDCS: Participants will receive HD-tDCS at 3 mA for 30 minutes, for between 5-30 sessions.
Main Study
Withdrawal by Subject
1
2
3
1
Main Study
Paused due to non-related illness, then became medically ineligible during pause
0
1
0
0

Baseline Characteristics

Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Sham Stimulation
n=59 Participants
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. Sham: Participants will receive sham (placebo) HD-tDCS for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
n=59 Participants
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. 1 mA HD-tDCS: Participants will receive HD-tDCS at 1 mA for 30 minutes, for between 5-30 sessions.
2 mA Dosage Stimulation
n=58 Participants
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. 2 mA HD-tDCS: Participants will receive HD-tDCS at 2 mA for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
n=57 Participants
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. 3 mA HD-tDCS: Participants will receive HD-tDCS at 3 mA for 30 minutes, for between 5-30 sessions.
Total
n=233 Participants
Total of all reporting groups
Age, Continuous
72.2 years
STANDARD_DEVIATION 7.5 • n=59 Participants
74.1 years
STANDARD_DEVIATION 8.0 • n=59 Participants
72.3 years
STANDARD_DEVIATION 5.7 • n=58 Participants
71.7 years
STANDARD_DEVIATION 6.9 • n=57 Participants
72.6 years
STANDARD_DEVIATION 7.2 • n=233 Participants
Sex: Female, Male
Female
31 Participants
n=59 Participants
21 Participants
n=59 Participants
26 Participants
n=58 Participants
30 Participants
n=57 Participants
108 Participants
n=233 Participants
Sex: Female, Male
Male
28 Participants
n=59 Participants
38 Participants
n=59 Participants
32 Participants
n=58 Participants
27 Participants
n=57 Participants
125 Participants
n=233 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
n=59 Participants
0 Participants
n=59 Participants
0 Participants
n=58 Participants
0 Participants
n=57 Participants
2 Participants
n=233 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
57 Participants
n=59 Participants
59 Participants
n=59 Participants
58 Participants
n=58 Participants
57 Participants
n=57 Participants
231 Participants
n=233 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=59 Participants
0 Participants
n=59 Participants
0 Participants
n=58 Participants
0 Participants
n=57 Participants
0 Participants
n=233 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=59 Participants
0 Participants
n=59 Participants
0 Participants
n=58 Participants
0 Participants
n=57 Participants
0 Participants
n=233 Participants
Race (NIH/OMB)
Asian
1 Participants
n=59 Participants
3 Participants
n=59 Participants
1 Participants
n=58 Participants
1 Participants
n=57 Participants
6 Participants
n=233 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=59 Participants
0 Participants
n=59 Participants
0 Participants
n=58 Participants
0 Participants
n=57 Participants
0 Participants
n=233 Participants
Race (NIH/OMB)
Black or African American
8 Participants
n=59 Participants
5 Participants
n=59 Participants
5 Participants
n=58 Participants
8 Participants
n=57 Participants
26 Participants
n=233 Participants
Race (NIH/OMB)
White
49 Participants
n=59 Participants
51 Participants
n=59 Participants
52 Participants
n=58 Participants
48 Participants
n=57 Participants
200 Participants
n=233 Participants
Race (NIH/OMB)
More than one race
1 Participants
n=59 Participants
0 Participants
n=59 Participants
0 Participants
n=58 Participants
0 Participants
n=57 Participants
1 Participants
n=233 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=59 Participants
0 Participants
n=59 Participants
0 Participants
n=58 Participants
0 Participants
n=57 Participants
0 Participants
n=233 Participants
Region of Enrollment
United States
59 participants
n=59 Participants
59 participants
n=59 Participants
58 participants
n=58 Participants
57 participants
n=57 Participants
233 participants
n=233 Participants
Multifactorial Memory Questionnaire (MMQ) Subsections
Contentment - Amyloid Negative participants
35.6 score on a scale
STANDARD_DEVIATION 7.73 • n=15 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
38.48 score on a scale
STANDARD_DEVIATION 12.08 • n=21 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
34.15 score on a scale
STANDARD_DEVIATION 12.44 • n=13 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
36.31 score on a scale
STANDARD_DEVIATION 15.95 • n=13 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
36.42 score on a scale
STANDARD_DEVIATION 12.03 • n=62 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
RBANS delayed recall subscale
Amyloid Negative participants
19.13 Score on a scale
STANDARD_DEVIATION 9.27 • n=15 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
18.45 Score on a scale
STANDARD_DEVIATION 8.31 • n=20 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
20.54 Score on a scale
STANDARD_DEVIATION 10.12 • n=13 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
21.31 Score on a scale
STANDARD_DEVIATION 4.53 • n=13 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
19.67 Score on a scale
STANDARD_DEVIATION 8.24 • n=61 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
Multifactorial Memory Questionnaire (MMQ) Subsections
Contentment - Amyloid Positive participants
29.4 score on a scale
STANDARD_DEVIATION 11.92 • n=40 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
29.19 score on a scale
STANDARD_DEVIATION 10.22 • n=31 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
28 score on a scale
STANDARD_DEVIATION 9.11 • n=39 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
33.16 score on a scale
STANDARD_DEVIATION 12.44 • n=37 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
29.93 score on a scale
STANDARD_DEVIATION 11.09 • n=147 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
Multifactorial Memory Questionnaire (MMQ) Subsections
Ability - Amyloid Negative participants
47.2 score on a scale
STANDARD_DEVIATION 10.69 • n=15 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
45.2 score on a scale
STANDARD_DEVIATION 15.92 • n=20 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
44.46 score on a scale
STANDARD_DEVIATION 14.69 • n=13 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
46.54 score on a scale
STANDARD_DEVIATION 11.6 • n=13 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
45.82 score on a scale
STANDARD_DEVIATION 13.35 • n=61 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
Multifactorial Memory Questionnaire (MMQ) Subsections
Ability- Amyloid Positive participants
43.27 score on a scale
STANDARD_DEVIATION 13.14 • n=41 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
44.26 score on a scale
STANDARD_DEVIATION 11.25 • n=31 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
44.73 score on a scale
STANDARD_DEVIATION 12.31 • n=40 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
49.33 score on a scale
STANDARD_DEVIATION 9.22 • n=36 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
45.34 score on a scale
STANDARD_DEVIATION 11.78 • n=148 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
RBANS delayed recall subscale
Amyloid Positive participants
8.95 Score on a scale
STANDARD_DEVIATION 7.69 • n=41 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
10.48 Score on a scale
STANDARD_DEVIATION 8.78 • n=31 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
11.05 Score on a scale
STANDARD_DEVIATION 9.33 • n=40 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
8.97 Score on a scale
STANDARD_DEVIATION 9.34 • n=38 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
9.83 Score on a scale
STANDARD_DEVIATION 8.76 • n=150 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
Multifactorial Memory Questionnaire (MMQ) Subsections
Strategies- Amyloid Negative participants
30.93 score on a scale
STANDARD_DEVIATION 9.61 • n=15 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
34.38 score on a scale
STANDARD_DEVIATION 14.83 • n=21 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
38.69 score on a scale
STANDARD_DEVIATION 11.53 • n=13 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
37.92 score on a scale
STANDARD_DEVIATION 8.67 • n=13 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
35.19 score on a scale
STANDARD_DEVIATION 11.96 • n=62 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
Multifactorial Memory Questionnaire (MMQ) Subsections
Strategies- Amyloid Positive participants
38 score on a scale
STANDARD_DEVIATION 11.19 • n=40 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
36.55 score on a scale
STANDARD_DEVIATION 10.52 • n=31 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
35.15 score on a scale
STANDARD_DEVIATION 10.61 • n=40 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
36.16 score on a scale
STANDARD_DEVIATION 12.08 • n=38 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
36.46 score on a scale
STANDARD_DEVIATION 11.08 • n=149 Participants • Analysis included all randomized participants with MMQ data and available amyloid PET biomarker data. Participants were excluded when MMQ data or amyloid PET data was not acquired.
Baseline RBANS total
Amyloid Negative participants
169.4 Score on a scale
STANDARD_DEVIATION 33.9 • n=15 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
181.32 Score on a scale
STANDARD_DEVIATION 22.91 • n=19 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
183.92 Score on a scale
STANDARD_DEVIATION 31.47 • n=13 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
184.08 Score on a scale
STANDARD_DEVIATION 20.25 • n=13 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
179.5 Score on a scale
STANDARD_DEVIATION 27.45 • n=60 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
Baseline RBANS total
Amyloid Positive participants
145.95 Score on a scale
STANDARD_DEVIATION 29.88 • n=40 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
155.23 Score on a scale
STANDARD_DEVIATION 33.95 • n=31 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
152.15 Score on a scale
STANDARD_DEVIATION 37.58 • n=40 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
140.69 Score on a scale
STANDARD_DEVIATION 36.44 • n=35 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
148.36 Score on a scale
STANDARD_DEVIATION 34.63 • n=146 Participants • Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data. Participants were excluded when RBANS data or amyloid PET data was not acquired.
NIH Toolbox Cognition Fluid Composite Score
Amyloid Negative participants
78.73 score on a scale
STANDARD_DEVIATION 15.1 • n=15 Participants • Analysis included all randomized participants with the NIH Toolbox Cognition Fluid Composite Score and available amyloid PET biomarker data. Participants were excluded when the composite score or amyloid PET data was not acquired.
77.75 score on a scale
STANDARD_DEVIATION 10.62 • n=16 Participants • Analysis included all randomized participants with the NIH Toolbox Cognition Fluid Composite Score and available amyloid PET biomarker data. Participants were excluded when the composite score or amyloid PET data was not acquired.
90.8 score on a scale
STANDARD_DEVIATION 12.62 • n=10 Participants • Analysis included all randomized participants with the NIH Toolbox Cognition Fluid Composite Score and available amyloid PET biomarker data. Participants were excluded when the composite score or amyloid PET data was not acquired.
83.92 score on a scale
STANDARD_DEVIATION 9.18 • n=13 Participants • Analysis included all randomized participants with the NIH Toolbox Cognition Fluid Composite Score and available amyloid PET biomarker data. Participants were excluded when the composite score or amyloid PET data was not acquired.
81.93 score on a scale
STANDARD_DEVIATION 12.74 • n=54 Participants • Analysis included all randomized participants with the NIH Toolbox Cognition Fluid Composite Score and available amyloid PET biomarker data. Participants were excluded when the composite score or amyloid PET data was not acquired.
NIH Toolbox Cognition Fluid Composite Score
Amyloid Positive participants
69.68 score on a scale
STANDARD_DEVIATION 12.24 • n=37 Participants • Analysis included all randomized participants with the NIH Toolbox Cognition Fluid Composite Score and available amyloid PET biomarker data. Participants were excluded when the composite score or amyloid PET data was not acquired.
76.88 score on a scale
STANDARD_DEVIATION 13.44 • n=24 Participants • Analysis included all randomized participants with the NIH Toolbox Cognition Fluid Composite Score and available amyloid PET biomarker data. Participants were excluded when the composite score or amyloid PET data was not acquired.
75.77 score on a scale
STANDARD_DEVIATION 12.82 • n=31 Participants • Analysis included all randomized participants with the NIH Toolbox Cognition Fluid Composite Score and available amyloid PET biomarker data. Participants were excluded when the composite score or amyloid PET data was not acquired.
70.96 score on a scale
STANDARD_DEVIATION 15.67 • n=28 Participants • Analysis included all randomized participants with the NIH Toolbox Cognition Fluid Composite Score and available amyloid PET biomarker data. Participants were excluded when the composite score or amyloid PET data was not acquired.
72.99 score on a scale
STANDARD_DEVIATION 13.67 • n=120 Participants • Analysis included all randomized participants with the NIH Toolbox Cognition Fluid Composite Score and available amyloid PET biomarker data. Participants were excluded when the composite score or amyloid PET data was not acquired.
Lateral Temporal Cortex Connectivity
Amyloid Negative Participants
0.152 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.071 • n=15 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
0.150 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.080 • n=18 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
0.192 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.071 • n=11 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
0.148 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.068 • n=10 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
0.159 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.074 • n=54 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
Lateral Temporal Cortex Connectivity
Amyloid Positive Participants
0.154 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.063 • n=37 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
0.145 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.042 • n=28 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
0.141 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.047 • n=38 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
0.151 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.034 • n=36 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
0.148 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.048 • n=139 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
Default Mode Network Connectivity
Amyloid Negative Participants
0.388 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.085 • n=15 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
0.372 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.072 • n=18 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
0.437 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.089 • n=11 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
0.413 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.123 • n=10 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
0.397 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.091 • n=54 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
Default Mode Network Connectivity
Amyloid Positive Participants
0.385 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.105 • n=37 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
0.357 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.071 • n=28 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
0.349 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.096 • n=38 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
0.375 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.083 • n=36 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
0.367 Fisher z-transformed Pearson correlation
STANDARD_DEVIATION 0.091 • n=139 Participants • Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.
Working Memory (0-back)
Amyloid Negative Participants
4.38 d' (dimensionless)
STANDARD_DEVIATION 1.02 • n=15 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
4.42 d' (dimensionless)
STANDARD_DEVIATION 0.694 • n=20 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
4.49 d' (dimensionless)
STANDARD_DEVIATION 0.607 • n=12 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
4.59 d' (dimensionless)
STANDARD_DEVIATION 0.664 • n=13 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
4.46 d' (dimensionless)
STANDARD_DEVIATION 0.752 • n=60 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
Working Memory (0-back)
Amyloid Positive Participants
4.42 d' (dimensionless)
STANDARD_DEVIATION 0.772 • n=39 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
4.35 d' (dimensionless)
STANDARD_DEVIATION 0.84 • n=30 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
4.42 d' (dimensionless)
STANDARD_DEVIATION 0.762 • n=39 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
4.40 d' (dimensionless)
STANDARD_DEVIATION 0.779 • n=37 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
4.40 d' (dimensionless)
STANDARD_DEVIATION 0.778 • n=145 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
Working Memory (2-back)
Amyloid Negative Participants
2.05 d' (dimensionless)
STANDARD_DEVIATION 0.968 • n=15 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
2.16 d' (dimensionless)
STANDARD_DEVIATION 1.18 • n=20 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
2.48 d' (dimensionless)
STANDARD_DEVIATION 1.04 • n=12 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
2.00 d' (dimensionless)
STANDARD_DEVIATION 0.609 • n=13 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
2.16 d' (dimensionless)
STANDARD_DEVIATION 0.987 • n=60 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
Working Memory (2-back)
Amyloid Positive Participants
1.90 d' (dimensionless)
STANDARD_DEVIATION 0.966 • n=38 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
2.21 d' (dimensionless)
STANDARD_DEVIATION 1.06 • n=29 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
1.96 d' (dimensionless)
STANDARD_DEVIATION 0.927 • n=37 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
1.62 d' (dimensionless)
STANDARD_DEVIATION 1.17 • n=36 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
1.91 d' (dimensionless)
STANDARD_DEVIATION 1.04 • n=140 Participants • Analysis included all randomized participants with N-back data and available amyloid PET biomarker data. Participants were excluded when N-back data or amyloid PET data was not acquired.
Paired Associates Task
Amyloid Negative Participants
0.58 Proportion of correct responses
STANDARD_DEVIATION 0.062 • n=13 Participants • Analysis included all randomized participants with Paired Associates data and available amyloid PET biomarker data. Participants were excluded when Paired Associates data or amyloid PET data was not acquired.
0.59 Proportion of correct responses
STANDARD_DEVIATION 0.097 • n=16 Participants • Analysis included all randomized participants with Paired Associates data and available amyloid PET biomarker data. Participants were excluded when Paired Associates data or amyloid PET data was not acquired.
0.608 Proportion of correct responses
STANDARD_DEVIATION 0.1 • n=11 Participants • Analysis included all randomized participants with Paired Associates data and available amyloid PET biomarker data. Participants were excluded when Paired Associates data or amyloid PET data was not acquired.
0.599 Proportion of correct responses
STANDARD_DEVIATION 0.051 • n=12 Participants • Analysis included all randomized participants with Paired Associates data and available amyloid PET biomarker data. Participants were excluded when Paired Associates data or amyloid PET data was not acquired.
0.593 Proportion of correct responses
STANDARD_DEVIATION 0.079 • n=52 Participants • Analysis included all randomized participants with Paired Associates data and available amyloid PET biomarker data. Participants were excluded when Paired Associates data or amyloid PET data was not acquired.
Paired Associates Task
Amyloid Positive Participants
0.579 Proportion of correct responses
STANDARD_DEVIATION 0.077 • n=33 Participants • Analysis included all randomized participants with Paired Associates data and available amyloid PET biomarker data. Participants were excluded when Paired Associates data or amyloid PET data was not acquired.
0.557 Proportion of correct responses
STANDARD_DEVIATION 0.058 • n=28 Participants • Analysis included all randomized participants with Paired Associates data and available amyloid PET biomarker data. Participants were excluded when Paired Associates data or amyloid PET data was not acquired.
0.584 Proportion of correct responses
STANDARD_DEVIATION 0.074 • n=36 Participants • Analysis included all randomized participants with Paired Associates data and available amyloid PET biomarker data. Participants were excluded when Paired Associates data or amyloid PET data was not acquired.
0.567 Proportion of correct responses
STANDARD_DEVIATION 0.057 • n=31 Participants • Analysis included all randomized participants with Paired Associates data and available amyloid PET biomarker data. Participants were excluded when Paired Associates data or amyloid PET data was not acquired.
0.573 Proportion of correct responses
STANDARD_DEVIATION 0.068 • n=128 Participants • Analysis included all randomized participants with Paired Associates data and available amyloid PET biomarker data. Participants were excluded when Paired Associates data or amyloid PET data was not acquired.

PRIMARY outcome

Timeframe: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Population: Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data from either baseline, relevant end point, or both. Data was analyzed using a mixed model, rather than paired analysis. Therefore, in some cases, number analyzed exceeds number of participants in expansion period. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.

Primary outcome focuses on default mode network (DMN) between-network functional connectivity because the lateral temporal cortex is a core component of the DMN. Between-network functional connectivity is estimated from fMRI data as strength of temporal coupling between the DMN and other high-level (association) brain networks. For each participant and time point, correlation-based connectivity (Pearson r; Fisher r-to-z transformed; arbitrary units) computed between DMN regions and other regions of the association cortex defined using standard functional atlas. Higher values reflect stronger functional connectivity between DMN and other regions. A Z-score's range is infinite. Expected value is between -3 to 3. Analyses conducted separately for amyloid negative (A-) and amyloid positive (A+) participants. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Outcome measures

Outcome measures
Measure
2 mA Dosage Stimulation
n=52 Participants
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
n=48 Participants
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Sham Stimulation
n=54 Participants
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
n=48 Participants
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Change in Lateral Temporal Cortex Connectivity
Change from Baseline to Post-Intervention Amyloid Negative (A-) Participants
-0.026 Fisher z-transformed Pearson correlation
Interval -0.056 to 0.003
-0.009 Fisher z-transformed Pearson correlation
Interval -0.039 to 0.021
-0.002 Fisher z-transformed Pearson correlation
Interval -0.027 to 0.023
0.005 Fisher z-transformed Pearson correlation
Interval -0.019 to 0.028
Change in Lateral Temporal Cortex Connectivity
Change from Baseline to Post-Intervention for Amyloid Positive (A+) Participants
0.013 Fisher z-transformed Pearson correlation
Interval -0.003 to 0.029
0.006 Fisher z-transformed Pearson correlation
Interval -0.01 to 0.022
-0.022 Fisher z-transformed Pearson correlation
Interval -0.039 to -0.006
-0.001 Fisher z-transformed Pearson correlation
Interval -0.019 to 0.018
Change in Lateral Temporal Cortex Connectivity
Change from Baseline to Post-Expansion for Amyloid Negative (A-) Participants
-0.058 Fisher z-transformed Pearson correlation
Interval -0.116 to 0.0
-0.029 Fisher z-transformed Pearson correlation
Interval -0.08 to 0.023
-0.018 Fisher z-transformed Pearson correlation
Interval -0.06 to 0.024
-0.015 Fisher z-transformed Pearson correlation
Interval -0.057 to 0.026
Change in Lateral Temporal Cortex Connectivity
Change from Baseline to Post-Expansion for Amyloid Positive (A+) Participants
0.005 Fisher z-transformed Pearson correlation
Interval -0.017 to 0.027
0.008 Fisher z-transformed Pearson correlation
Interval -0.019 to 0.035
-0.005 Fisher z-transformed Pearson correlation
Interval -0.028 to 0.018
-0.003 Fisher z-transformed Pearson correlation
Interval -0.034 to 0.028

SECONDARY outcome

Timeframe: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Population: Analysis included all randomized participants with recorded outcome measure and available amyloid PET biomarker data from either baseline, relevant end point, or both. Data was analyzed using a mixed model, rather than paired analysis. Therefore, in some cases, number analyzed exceeds number of participants in expansion period. Participants were excluded when outcome was not recorded or amyloid PET data was not acquired.

The Multifactorial Memory Questionnaire (MMQ) consists of three scales measuring separate aspects of metamemory. Items are rated on a 5-point Likert scale (0-4) based on the test taker's experiences over the previous two weeks. MMQ-Satisfaction (formerly called MMQ-Contentment) scale measures satisfaction, concern, and overall appraisal of one's own memory. Each of 18 statements is rated based on degree of agreement. The score range is 0 to 72, with higher scores indicating a higher degree of satisfaction. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Outcome measures

Outcome measures
Measure
2 mA Dosage Stimulation
n=52 Participants
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
n=51 Participants
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Sham Stimulation
n=55 Participants
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
n=52 Participants
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Self-Report of Contentment With Memory
Change from baseline to end of expansion- amyloid positive-participants
2.697 score on a scale
Interval -0.681 to 6.075
-1.328 score on a scale
Interval -5.793 to 3.137
0.242 score on a scale
Interval -3.084 to 3.568
1.900 score on a scale
Interval -3.026 to 6.826
Self-Report of Contentment With Memory
Change from baseline to post intervention- amyloid negative-participants
-1.003 score on a scale
Interval -5.253 to 3.248
-0.692 score on a scale
Interval -4.794 to 3.409
1.933 score on a scale
Interval -1.885 to 5.752
1.836 score on a scale
Interval -1.462 to 5.134
Self-Report of Contentment With Memory
Change from baseline to post intervention- amyloid positive participants
-0.801 score on a scale
Interval -3.196 to 1.595
-1.503 score on a scale
Interval -3.96 to 0.955
0.575 score on a scale
Interval -1.763 to 2.913
0.908 score on a scale
Interval -1.828 to 3.644
Self-Report of Contentment With Memory
Change from baseline to end of expansion- amyloid negative-participants
0.062 score on a scale
Interval -8.053 to 8.178
-4.095 score on a scale
Interval -10.801 to 2.61
4.957 score on a scale
Interval -1.253 to 11.168
3.848 score on a scale
Interval -2.297 to 9.993

SECONDARY outcome

Timeframe: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Population: Analysis included all randomized participants with recorded outcome measure and available amyloid PET biomarker data from either baseline, relevant end point, or both. Data was analyzed using a mixed model, rather than paired analysis. Therefore, in some cases, number analyzed exceeds number of participants in expansion period. Participants were excluded when outcome was not recorded or amyloid PET data was not acquired.

Multifactorial Memory Questionnaire (MMQ) Ability Score - This scale measures self-perception of everyday memory ability. Respondents rate how often they experienced each of 20 common memory mistakes over the previous two weeks. The score range is 0 to 80, with higher scores indicating better self-reported memory ability. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Outcome measures

Outcome measures
Measure
2 mA Dosage Stimulation
n=53 Participants
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
n=51 Participants
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Sham Stimulation
n=56 Participants
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
n=52 Participants
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Self-Report of Memory Mistakes
Change from baseline to post expansion- amyloid negative participants
-0.388 score on a scale
Interval -7.58 to 6.803
1.807 score on a scale
Interval -4.108 to 7.722
5.037 score on a scale
Interval -0.44 to 10.515
4.579 score on a scale
Interval -0.868 to 10.026
Self-Report of Memory Mistakes
Change from baseline to post intervention - amyloid negative participants
1.336 score on a scale
Interval -2.976 to 5.648
0.692 score on a scale
Interval -3.466 to 4.85
-1.267 score on a scale
Interval -5.138 to 2.604
3.475 score on a scale
Interval 0.053 to 6.897
Self-Report of Memory Mistakes
Change from baseline to post intervention - amyloid positive participants
0.907 score on a scale
Interval -1.519 to 3.333
-0.714 score on a scale
Interval -3.238 to 1.809
-0.365 score on a scale
Interval -2.733 to 2.002
0.444 score on a scale
Interval -2.331 to 3.219
Self-Report of Memory Mistakes
Change from baseline to post expansion- amyloid positive participants
5.565 score on a scale
Interval 2.587 to 8.543
0.434 score on a scale
Interval -3.425 to 4.294
3.040 score on a scale
Interval 0.122 to 5.959
4.458 score on a scale
Interval 0.103 to 8.812

SECONDARY outcome

Timeframe: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Population: Analysis included all randomized participants with recorded outcome measure and available amyloid PET biomarker data from either baseline, relevant end point, or both. Data was analyzed using a mixed model, rather than paired analysis. Therefore, in some cases, number analyzed exceeds number of participants in expansion period. Participants were excluded when outcome was not recorded or amyloid PET data was not acquired.

Multifactorial Memory Questionnaire (MMQ) Strategies Score - This scale measures the use of practical memory strategies and aids in day-to-day life. Respondents rate how often they used each of 19 memory strategies over the previous two weeks. The score range is 0 to 76, with higher scores indicating greater use of memory strategies. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Outcome measures

Outcome measures
Measure
2 mA Dosage Stimulation
n=53 Participants
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
n=51 Participants
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Sham Stimulation
n=55 Participants
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
n=52 Participants
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Self-Report of Memory Strategies Used
Change from baseline to post intervention - amyloid positive participants
-0.622 score on a scale
Interval -3.122 to 1.879
-1.258 score on a scale
Interval -3.766 to 1.25
0.900 score on a scale
Interval -1.516 to 3.316
-1.426 score on a scale
Interval -4.252 to 1.401
Self-Report of Memory Strategies Used
Change from baseline to post intervention - amyloid negative participants
0.419 score on a scale
Interval -3.972 to 4.81
2.078 score on a scale
Interval -2.313 to 6.469
2.333 score on a scale
Interval -1.612 to 6.279
2.926 score on a scale
Interval -0.481 to 6.333
Self-Report of Memory Strategies Used
Change from baseline to post expansion- amyloid negative participants
-1.599 score on a scale
Interval -8.717 to 5.519
-3.315 score on a scale
Interval -9.176 to 2.547
1.801 score on a scale
Interval -3.628 to 7.229
-1.083 score on a scale
Interval -6.47 to 4.304
Self-Report of Memory Strategies Used
Change from baseline to post expansion- amyloid positive participants
-0.092 score on a scale
Interval -3.046 to 2.863
1.664 score on a scale
Interval -2.155 to 5.482
-3.942 score on a scale
Interval -6.839 to -1.044
-3.251 score on a scale
Interval -7.563 to 1.061

SECONDARY outcome

Timeframe: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Population: Analysis included all randomized participants with RBANS data and available amyloid PET biomarker data from either baseline, relevant end point, or both. Data was analyzed using a mixed model, rather than paired analysis. Therefore, in some cases, number analyzed exceeds number of participants in expansion period. Participants were excluded when RBANS data or amyloid PET data was not acquired.

The Repeatable Battery of the Assessment of Neuropsychological Status (RBANS) is a comprehensive neuropsychological battery for the evaluation of global cognition. The delayed memory section is a measure of delayed recall and recognition for verbal and visual information. It includes the subtests List Recall, List Recognition, Story Memory, and Figure Recall. Low scores on this index indicate difficulties with recognition and retrieval of information from long-term memory stores This index is composed of both auditory and visual measures; therefore, a severe deficit in language, auditory processing, or visual functioning may impact one of the measures more than the other. Analysis included the sum of the raw scores for each of the delayed memory subtests, with possible scores ranging from 0 to 62. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Outcome measures

Outcome measures
Measure
2 mA Dosage Stimulation
n=53 Participants
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
n=51 Participants
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Sham Stimulation
n=56 Participants
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
n=52 Participants
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Change in Memory Functioning
Change from baseline to post intervention - amyloid positive participants
0.304 score on a scale
Interval -1.356 to 1.963
1.237 score on a scale
Interval -0.446 to 2.919
1.745 score on a scale
Interval 0.107 to 3.384
1.127 score on a scale
Interval -0.828 to 3.082
Change in Memory Functioning
Change from baseline to end of expansion- amyloid negative-participants
2.038 score on a scale
Interval -2.547 to 6.622
1.724 score on a scale
Interval -2.033 to 5.481
-0.579 score on a scale
Interval -4.057 to 2.9
1.323 score on a scale
Interval -2.421 to 5.066
Change in Memory Functioning
Change from baseline to end of expansion- amyloid positive-participant
-0.780 score on a scale
Interval -2.665 to 1.105
-2.088 score on a scale
Interval -4.632 to 0.457
-0.130 score on a scale
Interval -1.977 to 1.717
-0.378 score on a scale
Interval -3.28 to 2.524
Change in Memory Functioning
Change from baseline to post intervention - amyloid negative participants
3.088 score on a scale
Interval -0.027 to 6.202
2.462 score on a scale
Interval -0.415 to 5.338
3.400 score on a scale
Interval 0.722 to 6.078
3.164 score on a scale
Interval 0.73 to 5.598

SECONDARY outcome

Timeframe: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Population: Analysis included all randomized participants with recorded outcome measure and available amyloid PET biomarker data from either baseline, relevant end point, or both. Data was analyzed using a mixed model, rather than paired analysis. Therefore, in some cases, number analyzed exceeds number of participants in expansion period. Participants were excluded when outcome was not recorded or amyloid PET data was not acquired.

Cognitive function was determined using the NIH Toolbox-Cognition Battery computerized tests, specifically the Fluid composite score. It is derived by averaging the subtests in the Fluid domain to achieve an overall standard score. Fully Corrected T-scores are adjusted for for age, gender, race/ethnicity, and educational attainment. The score compares the score of the participant to those in the NIH Toolbox nationally representative normative sampling. The T-score has a mean of 50 in the general population and a SD of 10. Scores higher than the mean indicate better performance. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Outcome measures

Outcome measures
Measure
2 mA Dosage Stimulation
n=46 Participants
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
n=45 Participants
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Sham Stimulation
n=54 Participants
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
n=45 Participants
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Change in Overall Fluid Cognitive Abilities
Change from baseline to post intervention - amyloid negative participants
1.409 score on a scale
Interval -2.934 to 5.751
0.923 score on a scale
Interval -2.897 to 4.743
4.094 score on a scale
Interval 0.422 to 7.767
5.075 score on a scale
Interval 1.429 to 8.721
Change in Overall Fluid Cognitive Abilities
Change from baseline to post intervention - amyloid positive participants
1.090 score on a scale
Interval -1.68 to 3.861
2.466 score on a scale
Interval -0.489 to 5.42
2.815 score on a scale
Interval 0.242 to 5.389
2.399 score on a scale
Interval -0.579 to 5.376
Change in Overall Fluid Cognitive Abilities
Change from baseline to end of expansion- amyloid negative-participants
-0.364 score on a scale
Interval -8.418 to 7.69
2.793 score on a scale
Interval -3.103 to 8.69
6.478 score on a scale
Interval 1.018 to 11.939
12.891 score on a scale
Interval 5.145 to 20.638
Change in Overall Fluid Cognitive Abilities
Change from baseline to end of expansion- amyloid positive-participants
2.632 score on a scale
Interval -1.003 to 6.267
7.053 score on a scale
Interval 2.265 to 11.84
2.871 score on a scale
Interval -0.523 to 6.264
4.952 score on a scale
Interval -0.337 to 10.241

SECONDARY outcome

Timeframe: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Population: Analysis included all randomized participants with Nback data and available amyloid PET biomarker data. Participants were excluded when Nback data or amyloid PET data was not acquired.

The n-back test is a working memory task where participants identify stimulus that matches stimulus experienced "n" steps back. Participants performed a 2-back test, in which they were asked to remember and press a button when shown a stimulus that appeared 2 steps before the current one (e.g. square, circle, square). The number of correct and incorrect identifications are normalized (z-score). Total score is the z-score of correct button presses minus the z-score of incorrect button presses. A higher score (d') reflects better working memory performance. Possible scores range from -4.85 to 4.85. Positive change (increase) in 2-back score across treatment sessions indicates improvement in working memory performance. Data is shown as the mean slope calculation of participants across first 5 days of treatment and across all treatments, x=days of treatment, y=n-back score. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks.

Outcome measures

Outcome measures
Measure
2 mA Dosage Stimulation
n=53 Participants
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
n=51 Participants
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Sham Stimulation
n=56 Participants
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
n=52 Participants
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Cumulative Working Memory Effects of HD-tDCS Across Treatment Sessions
Slope across first 5 days of treatment for Amyloid Negative (A-) Participants
0.053 d'/day
Interval -0.04 to 0.145
0.021 d'/day
Interval -0.065 to 0.107
0.042 d'/day
Interval -0.04 to 0.124
0.027 d'/day
Interval -0.045 to 0.1
Cumulative Working Memory Effects of HD-tDCS Across Treatment Sessions
Slope across first 5 days of treatment for Amyloid Positive (A+) Participants
0.018 d'/day
Interval -0.032 to 0.069
0.045 d'/day
Interval -0.007 to 0.097
-0.011 d'/day
Interval -0.061 to 0.039
0.010 d'/day
Interval -0.05 to 0.07
Cumulative Working Memory Effects of HD-tDCS Across Treatment Sessions
Slope across entire treatment (up to 43 weeks) for Amyloid Negative (A-) Participants
0.037 d'/day
Interval -0.014 to 0.088
0.072 d'/day
Interval 0.025 to 0.118
0.068 d'/day
Interval 0.02 to 0.116
0.042 d'/day
Interval 0.001 to 0.084
Cumulative Working Memory Effects of HD-tDCS Across Treatment Sessions
Slope across entire treatment (up to 43 weeks) for Amyloid Positive (A+) Participants
0.028 d'/day
Interval 0.004 to 0.053
0.079 d'/day
Interval 0.05 to 0.108
0.045 d'/day
Interval 0.022 to 0.067
0.023 d'/day
Interval -0.012 to 0.057

SECONDARY outcome

Timeframe: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Population: Analysis included all randomized participants who completed the baseline computerized paired-associates task, had available amyloid PET biomarker data, were not identified as outliers, and for whom a valid model-based memory sensitivity estimate (baseline average) could be obtained. Participants were excluded when paired-associates data, amyloid PET data, or a valid model-based memory sensitivity estimate was not available.

Paired Associates task is a verbal memory task that asks participants to learn a list of word pairs. After a delay, participants are shown correct and mismatched word pairs one at a time and asked to identify if the displayed word pair was from the list they were asked to learn or not. Total accuracy is a proportion (total correct responses divided by total trials completed) ranging from 0 to 1 that measures the accuracy of a participant's responses to both correct and mismatched word pairs. Higher scores indicate better verbal memory performance, and positive changes over time indicate an improvement in verbal memory performance, measured after baseline (Session 1) and every intervention session (Sessions 2-5) Data is shown as the mean slope calculation of participants across first 5 days of treatment and across all treatments, x=days of treatment, y= total accuracy. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks.

Outcome measures

Outcome measures
Measure
2 mA Dosage Stimulation
n=53 Participants
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
n=51 Participants
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Sham Stimulation
n=56 Participants
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
n=50 Participants
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Cumulative Memory Accuracy Effects of HD-tDCS Across Treatment Sessions
Slope across first 5 days of treatment for Amyloid Negative (A-) Participants
0.006 proportion of correct responses/day
Interval -0.001 to 0.012
0.002 proportion of correct responses/day
Interval -0.004 to 0.009
0.001 proportion of correct responses/day
Interval -0.005 to 0.007
-0.001 proportion of correct responses/day
Interval -0.007 to 0.004
Cumulative Memory Accuracy Effects of HD-tDCS Across Treatment Sessions
Slope across first 5 days of treatment for Amyloid Positive (A+) Participants
-0.000 proportion of correct responses/day
Interval -0.004 to 0.004
-0.006 proportion of correct responses/day
Interval -0.01 to -0.002
0.001 proportion of correct responses/day
Interval -0.003 to 0.004
-0.003 proportion of correct responses/day
Interval -0.008 to 0.001
Cumulative Memory Accuracy Effects of HD-tDCS Across Treatment Sessions
Slope across entire treatment (up to 43 weeks) for Amyloid Negative (A-) Participants
0.009 proportion of correct responses/day
Interval 0.005 to 0.012
0.001 proportion of correct responses/day
Interval -0.003 to 0.004
0.001 proportion of correct responses/day
Interval -0.002 to 0.005
0.003 proportion of correct responses/day
Interval 0.0 to 0.006
Cumulative Memory Accuracy Effects of HD-tDCS Across Treatment Sessions
Slope across entire treatment (up to 43 weeks) for Amyloid Positive (A+) Participants
0.002 proportion of correct responses/day
Interval 0.0 to 0.003
-0.001 proportion of correct responses/day
Interval -0.003 to 0.001
0.001 proportion of correct responses/day
Interval -0.001 to 0.002
0.002 proportion of correct responses/day
Interval 0.0 to 0.005

SECONDARY outcome

Timeframe: Baseline

Population: Analysis included all randomized participants who completed the baseline computerized paired-associates task, had available amyloid PET biomarker data, were not identified as outliers, and for whom a valid model-based memory sensitivity estimate (baseline average) could be obtained. Participants were excluded when paired-associates data, amyloid PET data, or a valid model-based memory sensitivity estimate was not available.

Verbal memory performance for computerized Paired Associates task, summarized with a computational model (linear ballistic accumulator decision model). The model uses each participant's accuracy and reaction times across trials to estimate how efficiently they accumulate information to distinguish previously studied (target) word pairs from new (lure) pairs. Reported outcome is the average memory sensitivity score at baseline, expressed as unitless model values (scores on a scale) where higher scores indicate better discrimination, scores near zero indicate chance-level performance, and negative scores (if present) indicate performance worse than chance.

Outcome measures

Outcome measures
Measure
2 mA Dosage Stimulation
n=45 Participants
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
n=42 Participants
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Sham Stimulation
n=44 Participants
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
n=41 Participants
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Cumulative Memory Sensitivity Effects of HD-tDCS Across Daily Sessions
Amyloid Negative Participants
0.608 arbitrary units
Standard Deviation 0.558
0.425 arbitrary units
Standard Deviation 0.226
0.407 arbitrary units
Standard Deviation 0.225
0.420 arbitrary units
Standard Deviation 0.430
Cumulative Memory Sensitivity Effects of HD-tDCS Across Daily Sessions
Amyloid Positive Participants
0.417 arbitrary units
Standard Deviation 0.295
0.375 arbitrary units
Standard Deviation 0.260
0.402 arbitrary units
Standard Deviation 0.302
0.286 arbitrary units
Standard Deviation 0.277

SECONDARY outcome

Timeframe: Assessed immediately after each HD-tDCS session (participants received up to 30 sessions over approximately 1-12 weeks); values represent mean symptom burden averaged across all post-stimulation assessments

Population: Of 233 enrolled participants, 232 were included in the analysis (N=232 participants, 3196 sessions). One participant from the 2 mA group was excluded due to missing symptom data. Five individual sessions across all groups were excluded due to incomplete symptom assessments.

Tolerability was assessed using the HD-tDCS Safety Questionnaire, an 11-item symptom checklist. The questionnaire assesses the presence (yes/no) of 10 specific self-reported symptoms (Itching, Burning, Tingling, Scalp Pain, Trouble Concentrating, Sleep problems, Headache, Mood Change, Neck Pain, and Other symptoms) and 1 oberserved symptom, Skin Redness. Skin Redness was excluded from this analysis as it is not related to the participant's perception of tolerability. The total score (symptom burden) was calculated by summing the number of symptoms present across the 10 items for each session. Score range: 0 to 10 symptoms, where 0 = no symptoms present and 10 = all symptoms present. Higher scores indicate worse tolerability (more symptoms experienced). Values represent the mean number of symptoms per session, calculated by averaging symptom burden scores across all post-stimulation assessments within each treatment group.

Outcome measures

Outcome measures
Measure
2 mA Dosage Stimulation
n=57 Participants
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
n=57 Participants
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Sham Stimulation
n=59 Participants
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
n=59 Participants
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Tolerability of HD-tDCS
1.46 symptoms on a scale (0-10)
Standard Deviation 1.45
1.39 symptoms on a scale (0-10)
Standard Deviation 1.16
1.19 symptoms on a scale (0-10)
Standard Deviation 1.1
1.1 symptoms on a scale (0-10)
Standard Deviation 1.09

SECONDARY outcome

Timeframe: Assessed immediately after each HD-tDCS session (participants received up to 30 sessions over approximately 1-12 weeks)

Population: Of 233 enrolled participants, 232 were included in the blinding effectiveness analysis (N=232 participants, 3185 sessions). One participant was excluded due to having no valid blinding assessments. Sessions were excluded due to missing blinding responses. Missing sessions are due to participant refusal to answer and the blinding assessment not being administered. Cumulative link mixed model with participant as random effect was used to account for repeated measures.

Participant's perception of treatment assignment assessed after each stimulation session using a 3-category ordinal scale. Participants guessed whether they received: (0) Sham stimulation, (1) Don't Know, or (2) Active stimulation. The scale is ordinal with Sham \< Don't Know \< Active. Effective blinding is indicated by no significant difference in the distribution of perceived assignment between active and sham groups (i.e., participants in active groups cannot reliably distinguish their treatment from sham). Higher proportional odds ratios would indicate active group participants were more likely to guess "active"; lower ratios would indicate sham participants were more likely to guess "active" (paradoxical pattern suggesting convincing sham condition).

Outcome measures

Outcome measures
Measure
2 mA Dosage Stimulation
n=849 tDCS sessions
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
n=730 tDCS sessions
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Sham Stimulation
n=900 tDCS sessions
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
n=706 tDCS sessions
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Effectiveness of Blinding of HD-tDCS
Chose sham
36 sessions
36 sessions
17 sessions
28 sessions
Effectiveness of Blinding of HD-tDCS
Didn't know
500 sessions
425 sessions
474 sessions
468 sessions
Effectiveness of Blinding of HD-tDCS
Chose active
313 sessions
269 sessions
409 sessions
210 sessions

SECONDARY outcome

Timeframe: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Population: Analysis included all randomized participants with usable MRI data and available amyloid PET biomarker data from either baseline, relevant end point, or both. Data was analyzed using a mixed model, rather than paired analysis. Therefore, in some cases, number analyzed exceeds number of participants in expansion period. Participants were excluded when MRI data could not be reliably processed (segmentation/quality failures or excessive head motion) or amyloid PET data was not acquired.

The outcome focuses on default mode network (DMN) within-network functional connectivity. Within-network functional connectivity is estimated from fMRI data as strength of temporal coupling within DMN regions (nodes). For each participant and time point, correlation-based connectivity (Pearson r; Fisher r-to-z transformed; arbitrary units) was computed between DMN regions defined using a standard functional atlas. Higher values reflect stronger functional connectivity within DMN. A Z-score's range is infinite. Expected value is around -3 to 3. Analyses are conducted separately for amyloid negative (A-) and amyloid positive (A+) participants. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Outcome measures

Outcome measures
Measure
2 mA Dosage Stimulation
n=52 Participants
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
n=48 Participants
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Sham Stimulation
n=54 Participants
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
n=48 Participants
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Change in Default Mode Network Connectivity
Change from Baseline to Post-Intervention Amyloid Negative (A-) Participants
-0.033 Fisher z-transformed Pearson correlation
Interval -0.084 to 0.018
-0.020 Fisher z-transformed Pearson correlation
Interval -0.071 to 0.032
0.031 Fisher z-transformed Pearson correlation
Interval -0.011 to 0.074
0.020 Fisher z-transformed Pearson correlation
Interval -0.021 to 0.06
Change in Default Mode Network Connectivity
Change from Baseline to Post-Intervention for Amyloid Positive (A+) Participants
0.011 Fisher z-transformed Pearson correlation
Interval -0.016 to 0.038
-0.002 Fisher z-transformed Pearson correlation
Interval -0.029 to 0.026
-0.002 Fisher z-transformed Pearson correlation
Interval -0.029 to 0.026
-0.007 Fisher z-transformed Pearson correlation
Interval -0.039 to 0.025
Change in Default Mode Network Connectivity
Change from Baseline to Post-Expansion for Amyloid Negative (A-) Participants
0.036 Fisher z-transformed Pearson correlation
Interval -0.059 to 0.131
-0.030 Fisher z-transformed Pearson correlation
Interval -0.114 to 0.054
0.011 Fisher z-transformed Pearson correlation
Interval -0.057 to 0.08
-0.005 Fisher z-transformed Pearson correlation
Interval -0.073 to 0.063
Change in Default Mode Network Connectivity
Change from Baseline to Post-Expansion for Amyloid Positive (A+) Participants
0.013 Fisher z-transformed Pearson correlation
Interval -0.022 to 0.048
0.001 Fisher z-transformed Pearson correlation
Interval -0.043 to 0.045
0.016 Fisher z-transformed Pearson correlation
Interval -0.021 to 0.054
0.026 Fisher z-transformed Pearson correlation
Interval -0.024 to 0.077

SECONDARY outcome

Timeframe: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Population: Due to financial constraints, Cogstate software was not able to be used for this study and no data was collected for this measure. "Other comparable computerized cognitive testing scores" as described in the Outcome Measure Description are reported in Secondary Outcome 7 and 8.

Measured through change in Cogstate or other comparable computerized cognitive testing scores across consecutive daily sessions.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Population: Analysis included all randomized participants with recorded outcome measure and available amyloid PET biomarker data from either baseline, relevant end point, or both. Data was analyzed using a mixed model, rather than paired analysis. Therefore, in some cases, number analyzed exceeds number of participants in expansion period. Participants were excluded when outcome was not recorded or amyloid PET data was not acquired.

The Repeatable Battery of the Assessment of Neuropsychological Status (RBANS) is a comprehensive neuropsychological battery for the evaluation of global cognition and has been validated in subjects with mild cognitive impairment, moderate to severe traumatic brain injuries, vascular dementias, and Alzheimer's disease. Data was analyzed using the sum of the subtest raw scores, which is an indicator of the general cognitive functioning of the examinee. Low scores suggest general cognitive impairment even when some individual subtest scores may be within normal limits. Individuals with low scores on this measure exhibit problems with attention, memory, language, and construction skills. Possible scores range from 0 to 321. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Outcome measures

Outcome measures
Measure
2 mA Dosage Stimulation
n=53 Participants
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
n=51 Participants
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Sham Stimulation
n=55 Participants
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
n=52 Participants
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
Change in Global Cognition
Change from baseline to end of expansion- amyloid negative-participants
1.415 score on a scale
Interval -9.975 to 12.806
5.582 score on a scale
Interval -3.741 to 14.904
5.649 score on a scale
Interval -2.983 to 14.281
1.752 score on a scale
Interval -7.549 to 11.052
Change in Global Cognition
Change from baseline to post intervention - amyloid positive participants
2.924 score on a scale
Interval -0.885 to 6.733
3.729 score on a scale
Interval -0.345 to 7.803
6.571 score on a scale
Interval 2.762 to 10.38
4.448 score on a scale
Interval -0.042 to 8.939
Change in Global Cognition
Change from baseline to end of expansion- amyloid positive-participants
-0.078 score on a scale
Interval -4.749 to 4.594
-3.320 score on a scale
Interval -9.878 to 3.238
0.479 score on a scale
Interval -4.192 to 5.151
3.570 score on a scale
Interval -4.024 to 11.165
Change in Global Cognition
Change from baseline to post intervention - amyloid negative participants
8.609 score on a scale
Interval 1.45 to 15.768
1.308 score on a scale
Interval -5.293 to 7.908
14.867 score on a scale
Interval 8.722 to 21.011
6.144 score on a scale
Interval 0.548 to 11.739

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and post-intervention (after tDCS sessions 5 & 30)

A priori intent to measure through change in the NIH Toolbox Flanker Inhibitory Control and Attention Test Score

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and post-intervention (after tDCS sessions 5 & 30)

A priori intent to measure through change in the NIH Toolbox Dimensional Change Card Sort Test Score

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and post-intervention (after tDCS sessions 5 & 30)

A priori intent to measure through change in the NIH Toolbox Picture Sequence Memory Test Score

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and post-intervention (after tDCS sessions 5 & 30)

A priori intent to measure through change in the NIH Toolbox List Sorting Working Memory Test Score

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and post-intervention (after tDCS sessions 5 & 30)

A priori intent to measure through change in the NIH Toolbox Pattern Comparison Processing Speed Test Score

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and post-intervention (after tDCS sessions 5 & 30)

Measured through change in the RBANS Visuospatial Index score

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and post-intervention (after tDCS sessions 5 & 30)

Measured through change in the RBANS Language Index score

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and post-intervention (after tDCS sessions 5 & 30)

Measured through change in the RBANS Attention Index score

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and post-intervention (after tDCS sessions 5 & 30)

Measured through change in the RBANS Immediate Memory Index score

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and post-intervention (after tDCS sessions 5 & 30)

A priori intent to measure through changes in RBANS subtest scores

Outcome measures

Outcome data not reported

Adverse Events

Sham Stimulation

Serious events: 0 serious events
Other events: 58 other events
Deaths: 0 deaths

1 mA Dosage Stimulation

Serious events: 1 serious events
Other events: 56 other events
Deaths: 0 deaths

2 mA Dosage Stimulation

Serious events: 1 serious events
Other events: 55 other events
Deaths: 0 deaths

3 mA Dosage Stimulation

Serious events: 0 serious events
Other events: 56 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Sham Stimulation
n=59 participants at risk
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. Sham: Participants will receive sham (placebo) HD-tDCS for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
n=59 participants at risk
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. 1 mA HD-tDCS: Participants will receive HD-tDCS at 1 mA for 30 minutes, for between 5-30 sessions.
2 mA Dosage Stimulation
n=58 participants at risk
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. 2 mA HD-tDCS: Participants will receive HD-tDCS at 2 mA for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
n=57 participants at risk
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. 3 mA HD-tDCS: Participants will receive HD-tDCS at 3 mA for 30 minutes, for between 5-30 sessions.
General disorders
Weakness between stimulation treatments
0.00%
0/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
0.00%
0/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
1.7%
1/58 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
0.00%
0/57 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
General disorders
Fall post enrollment and prior to stimulation treatment
0.00%
0/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
1.7%
1/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
0.00%
0/58 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
0.00%
0/57 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.

Other adverse events

Other adverse events
Measure
Sham Stimulation
n=59 participants at risk
Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. Sham: Participants will receive sham (placebo) HD-tDCS for 30 minutes, for between 5-30 sessions.
1 mA Dosage Stimulation
n=59 participants at risk
1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. 1 mA HD-tDCS: Participants will receive HD-tDCS at 1 mA for 30 minutes, for between 5-30 sessions.
2 mA Dosage Stimulation
n=58 participants at risk
2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. 2 mA HD-tDCS: Participants will receive HD-tDCS at 2 mA for 30 minutes, for between 5-30 sessions.
3 mA Dosage Stimulation
n=57 participants at risk
3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions. 3 mA HD-tDCS: Participants will receive HD-tDCS at 3 mA for 30 minutes, for between 5-30 sessions.
General disorders
Headache
8.5%
5/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
13.6%
8/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
13.8%
8/58 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
8.8%
5/57 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
Skin and subcutaneous tissue disorders
Burning sensation on scalp
66.1%
39/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
45.8%
27/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
58.6%
34/58 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
75.4%
43/57 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
Skin and subcutaneous tissue disorders
Itching
49.2%
29/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
47.5%
28/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
39.7%
23/58 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
45.6%
26/57 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
Skin and subcutaneous tissue disorders
Tingling on scalp
93.2%
55/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
81.4%
48/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
87.9%
51/58 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
80.7%
46/57 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
General disorders
Pain on scalp
32.2%
19/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
20.3%
12/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
22.4%
13/58 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
31.6%
18/57 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
General disorders
Trouble concentrating
22.0%
13/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
15.3%
9/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
32.8%
19/58 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
35.1%
20/57 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
General disorders
Sleepiness
11.9%
7/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
11.9%
7/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
12.1%
7/58 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
12.3%
7/57 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
General disorders
Mood change
22.0%
13/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
20.3%
12/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
25.9%
15/58 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
31.6%
18/57 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
Musculoskeletal and connective tissue disorders
Neck pain
6.8%
4/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
3.4%
2/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
10.3%
6/58 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
5.3%
3/57 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
Skin and subcutaneous tissue disorders
Skin redness
18.6%
11/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
32.2%
19/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
25.9%
15/58 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
49.1%
28/57 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
General disorders
Pulsing, tapping, tickling sensation
8.5%
5/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
5.1%
3/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
3.4%
2/58 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
1.8%
1/57 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
Skin and subcutaneous tissue disorders
Pricking, probing sensation on scalp
5.1%
3/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
5.1%
3/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
0.00%
0/58 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
5.3%
3/57 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
General disorders
Pressure in head
0.00%
0/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
1.7%
1/59 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
6.9%
4/58 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.
0.00%
0/57 • Up to 43 weeks)
Participants were followed during their participation in the trial. This duration varied significantly between participants due to participant availability and COVID restrictions.

Additional Information

Dr. Benjamin Hampstead

University of Michigan

Phone: 734-936-6185

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place